Laboratoire de Parasitologie, Mycologie Médicale et Pathologie Exotique, Université Claude Bernard Lyon I, 8 avenue Rockefeller, 69373 Lyon Cedex, France
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although reference methods for susceptibility testing of yeasts have been developed, susceptibility testing of filamentous fungi to antifungal drugs is not well standardized, and testing conditions are still being evaluated.1 In vitro, resistance of Aspergillus spp. to itraconazole has been described recently,2,3 but the frequency of this resistance is largely unknown. Moreover, correlation between these in-vitro results and in-vivo outcome in animal models with some Aspergillus spp. strains showed that resistance detected in vitrocould have clinical relevance.3,4
The current study was undertaken to determine the distribution of amphotericin B and itraconazole MICs by testing a large number of clinical isolates of Aspergillus spp. belonging to the five major species recovered from human infections.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Two-hundred-and-thirty isolates from 130 patients, comprising 156 Aspergillus fumigatus, 20 Aspergillus terreus, 22 Aspergillus flavus, 17 Aspergillus nidulans and 15 Aspergillus niger, were tested. The isolates were collected from 130 patients between January 1996 and August 1998, and were stored as conidial suspensions at -80°C in 10% glycerol until testing was initiated. An isolate of Candida krusei (ATCC 6258) was included as a control in each set of MIC determinations.
Susceptibility testing
Amphotericin B (Sigma, St Louis, MO, USA) and itraconazole (Janssen Pharmaceutica, Beerse, Belgium) were dissolved in dimethylsulphoxide (Sigma) to a concentration of 1600 mg/L and stored at -80°C as stock solutions.
Susceptibility testing was performed using a NCCLS-based broth microdilution technique.1 RPMI 1640 (Gibco-BRL, Uxbridge, UK) with L-glutamine and without sodium bicarbonate, and buffered at pH 7.0 with 0.165 M morpholinepropanesulphonic acid (MOPS), was used as test medium. The 2 x drug dilutions (32 to 0.06 mg/L) were prepared with medium used as the diluent, and dispensed into rows two to 11 of 96 U-shaped well microplates in 100 µL volumes. Row one contained 200 µL of uninoculated, drug-free medium and the wells of row 12 were used as growth controls.
The isolates were grown on malt extract agar (MEA) slants (Sanofi Diagnostics Pasteur, Marnes La Coquette, France) for 5 days at 35°C. The isolate of C. krusei (ATCC 6258) was grown on the same agar for 24 h at 35°C. The surface of the agar slants were washed over with 1 mL of sterile 0.9% saline containing 0.05% Tween 80, and the conidial suspensions were counted manually with a haemocytometer. The conidia were diluted in RPMI to produce a working suspension of 2 x 104 conidia/mL. Each well of rows two to 12 was inoculated with 100 µL of the 2 x conidial suspension. Hence, the final drug concentrations were 0.0316 mg/L for both drugs, and the final inoculum concentration was 104 conidia/mL. The MICs for all isolates were determined in duplicate. Microplates were incubated at 35°C for 48 h, and the growth in each well was compared with that of the growth control with the aid of a reading mirror. Each well was then given a numerical score from four (no reduction in growth) to zero (absence of growth).1
MIC endpoints were defined as the lowest drug concentration to have a score of one for itraconazole and zero for amphotericin B. The difference in the distributions of amphotericin B and itraconazole MICs was determined with a one-way analysis of variance.
![]() |
Results and discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The MICs of itraconazole ranged from 0.12 to >16 mg/L. There were no statistically significant differences between paired species for itraconazole. MICs >16 mg/L were detected for four A. fumigatus isolates and one A. nidulans isolate. These MICs were reproducible and the srains were considered to be resistant.
One A. fumigatus isolate resistant to itraconazole was cultured from the sputum of a patient who was treated with amphotericin B and 5-fluorocytosine for an Aspergillus spp. brain abcess. This patient had not received itraconazole before the strain was isolated. A second A. fumigatus isolate resistant to itraconazole was cultured from a patient with aspergilloma. This patient received itraconazole for several months before the strain was isolated. The two other resistant A. fumigatus isolates were cultured from broncho-alveolar lavages from a patient treated with itraconazole for a chronic necrotizing pulmonary aspergillosis. From this patient, A. fumigatus isolates with an itraconazole MIC of 0.5 mg/L were cultured initially, and after 4 months of treatment with itraconazole, two isolates were found to be resistant. This case suggests either the possibility of development of resistance, or secondary contamination by an itraconazole-resistant strain. Genomic analysis of these isolates will be necessary to clarify this.
Several studies have shown that in-vitro activity of itraconazole against A. fumigatus is high, and in some of these studies no itraconazole-resistant isolates have been identified.8,9 Nevertheless, in a large series using an NCCLS procedure, it was reported that three patients were infected with A. fumigatus strains that acquired in-vitro resistance to itraconazole (MIC > 32 mg/L) during prolonged therapy.2 Moreover, three itraconazole-resistant strains of A. fumigatus from two patients have been recently detected and the resistance has been confirmed in an animal model.3 Our data confirm previous studies demonstrating in-vitro resistance of A. fumigatus to itraconazole, although the frequency of this resistance appears to be low.
The A. nidulans isolate was cultured from a patient who did not receive any antifungal treatment, suggesting that primary itraconazole resistance can be detected in non-fumigatus Aspergillus spp.
Further studies with a larger number of isolates are required to establish the frequency of itraconazole resistance for the different Aspergillus spp. The in-vitro data obtained in this and other studies2,3 suggest that Aspergillus spp. can be resistant to itraconazole. Since there is little information regarding the clinical relevance of in-vitro data for moulds, these results should first be validated in vivo.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Chryssanthou, E. (1997). In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scandinavian Journal of Infectious Diseases 29, 50912.[ISI][Medline]
3 . Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A. et al. (1997). Itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 41, 13648.[Abstract]
4 . Denning, D. W., Radford, S. A., Oakley, K. L., Hall, L., Johnson, E. M. & Warnock, D. W. (1997). Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. Journal of Antimicrobial Chemotherapy 40, 40114.[Abstract]
5 . Oakley, K. L., Moore, C. B. & Denning, D. W. (1998). In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. Journal of Antimicrobial Chemotherapy 42, 914.[Abstract]
6 . National Committe for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA.
7
.
Verweij, P. E., Oakley, K. L., Morrissey, J., Morrissey, G.
& Denning, D. W. (1998). Efficacy of LY303366 against amphotericin
B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive
aspergillosis. Antimicrobial Agents and Chemotherapy 42, 8738.
8 . Manavathu, E. K., Alangaden, G. J. & Lerner, S. A. (1996). A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Canadian Journal of Microbiology 42, 9604.[ISI][Medline]
9 . Verweij, P. E., Mensink, M., Rijs, A. J., Donnelly, J. P., Meis, J. F. & Denning, D. W. (1998). In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. Journal of Antimicrobial Chemotherapy 42, 38992.[Abstract]
Received 7 December 1998; returned 13 March 1999; revised 7 April 1999; accepted 4 June 1999